MFN2 and neoplasm: For example, in pancreatic carcinoma, TF10, a bispecific anti-PAM4 (expressed by pancreatic carcinoma) and anti-HSG was developed for nuclear imaging and radioimmunotherapy, and where radiation dose estimates suggested that TF10/90Y-peptide pretargeting would provide a greater anti-tumor effect compared to 90Y-IgG [31].